Literature DB >> 10886110

The impact of molecular medicine upon early cardiovascular drug development.

M W Lunnon1, M Braddock.   

Abstract

Mesh：

Substances：

Year:  2000        PMID： 10886110      PMCID： PMC2014961          DOI： 10.1046/j.1365-2125.2000.00211.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  68 in total

1.  Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia.

Authors:  D W Losordo; P R Vale; J F Symes; C H Dunnington; D D Esakof; M Maysky; A B Ashare; K Lathi; J M Isner
Journal:  Circulation       Date:  1998 Dec 22-29       Impact factor: 29.690

2.  Deletion polymorphism in the angiotensin-converting enzyme gene as a thrombophilic risk factor after hip arthroplasty.

Authors:  C S Philipp; A Dilley; P Saidi; B Evatt; H Austin; J Zawadsky; D Harwood; D Ellingsen; E Barnhart; D J Phillips; W C Hooper
Journal:  Thromb Haemost       Date:  1998-12       Impact factor: 5.249

3.  In vivo transfection of cis element "decoy" against nuclear factor-kappaB binding site prevents myocardial infarction.

Authors:  R Morishita; T Sugimoto; M Aoki; I Kida; N Tomita; A Moriguchi; K Maeda; Y Sawa; Y Kaneda; J Higaki; T Ogihara
Journal:  Nat Med       Date:  1997-08       Impact factor: 53.440

4.  Possible involvement of stress-activated protein kinase signaling pathway and Fas receptor expression in prevention of ischemia/reperfusion-induced cardiomyocyte apoptosis by carvedilol.

Authors:  T L Yue; X L Ma; X Wang; A M Romanic; G L Liu; C Louden; J L Gu; S Kumar; G Poste; R R Ruffolo; G Z Feuerstein
Journal:  Circ Res       Date:  1998-02-09       Impact factor: 17.367

5.  Inhibition of neointimal cell bcl-x expression induces apoptosis and regression of vascular disease.

Authors:  M J Pollman; J L Hall; M J Mann; L Zhang; G H Gibbons
Journal:  Nat Med       Date:  1998-02       Impact factor: 53.440

6.  Pharmacokinetics and tissue localization of antisense oligonucleotides in balloon-injured pig coronary arteries after local delivery with an iontophoretic balloon catheter.

Authors:  K A Robinson; N A Chronos; E Schieffer; S J Palmer; G D Cipolla; P G Milner; R G Walsh; S B King
Journal:  Cathet Cardiovasc Diagn       Date:  1997-07

7.  Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: the PREVENT single-centre, randomised, controlled trial.

Authors:  M J Mann; A D Whittemore; M C Donaldson; M Belkin; M S Conte; J F Polak; E J Orav; A Ehsan; G Dell'Acqua; V J Dzau
Journal:  Lancet       Date:  1999-10-30       Impact factor: 79.321

Review 8.  Structural and functional analysis of hypoxia-inducible factor 1.

Authors:  G L Semenza; F Agani; G Booth; J Forsythe; N Iyer; B H Jiang; S Leung; R Roe; C Wiener; A Yu
Journal:  Kidney Int       Date:  1997-02       Impact factor: 10.612

9.  A prospective evaluation of an angiotensin-converting-enzyme gene polymorphism and the risk of ischemic heart disease.

Authors:  K Lindpaintner; M A Pfeffer; R Kreutz; M J Stampfer; F Grodstein; F LaMotte; J Buring; C H Hennekens
Journal:  N Engl J Med       Date:  1995-03-16       Impact factor: 91.245

10.  Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study.

Authors:  T Koster; F R Rosendaal; H de Ronde; E Briët; J P Vandenbroucke; R M Bertina
Journal:  Lancet       Date:  1993 Dec 18-25       Impact factor: 79.321
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.